RecruitingPhase 2NCT07336797

Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy

Studying NON RARE IN EUROPE: Metabolic syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Abdelrahman Mahmoud
Principal Investigator
Maggie Abbassi, Prof.
Cairo University
Intervention
Empagliflozin (oral)(drug)
Enrollment
66 target
Eligibility
18-65 years · All sexes
Timeline
20252027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07336797 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Metabolic syndrome

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Metabolic syndrome

← Back to all trials